Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1608 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed553    
    Printed33    
    Emailed0    
    PDF Downloaded56    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 2002  |  Volume : 44  |  Issue : 4  |  Page : 365-371

Comparative Efficacy of Centbutindole & Risperidone in Schizophrenia


1 Formerly Junior Resident, Department of Psychiatry, C. S. M. Medical University (Upgraded K.G Medical College), Lucknow, India
2 Professor, Department of Psychiatry, C. S. M. Medical University (Upgraded K.G Medical College), Lucknow, India
3 Dy. Director & Head, Division of Clinical & Experimental Medicine, Central Drug Research Institute, Lucknow, India
4 Scientist E- ll, Division of Clinical & Experimental Medicine, Central Drug Research Institute, Lucknow, India

Correspondence Address:
R Chandra
Department of Psychiatry, UCMS & GTB Hospital, Dilshad Garden, Shahdara, Delhi-95
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21206602

Rights and PermissionsRights and Permissions

Centbutindole is a new antipsychotic agent related to butyrophenone group. The drug is dopamine antagonist but it also blocks 5HT2 receptors. Clinically the drug has passed through phase I, II & III clinical trials successfully and it has shown effective antipsychotic activity in schizophrenic patients. In the present study the drug was compared with risperidone in a double blind manner for a period of 8 weeks to assess the efficacy in schizophrenic patients. Patients of schizophrenia evaluated on PANSS, CGI & UKU side effect rating scale weekly Out of 44 patients included in study, 38 completed the trial. The intergroup comparison of two drugs showed that centbudindole and risperidone have similar onset of antipsychotic action as both the drugs showed significant decrease in the total PANSS score as well as positive syndrome score, negative syndrome score and general psychopathology score from 2nd week onwards. The scores in both the groups showed a steady and significant decline from 2nd week to 8th week of study. The present study showed that centbutindole has similar improvement on clinical global impression with risperidone. The side effect profile was similar in the two drugs except dystonia (5 patients in centbutindole vs 1 patient in risperidone group). The findings of present study shows that Centbutindole could be used as a promising new drug for treatment of schizophrenia in place of a typical antipsychotics as it has shown improvement on negative symptoms similar to risperidone.



[PDF]*

        

Print this article         Email this article